Veradermics: Phase 2 VDPHL01 shows 22.7-23.3 hairs/cm² increase, 88.9-90% improved at Month 6

Veradermics, Inc

Mean non-vellus hair count increase of 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily) at Month 6.
88.9% (once daily) and 90.0% (twice daily) of patients reported 'improved' or 'much improved' on AAIRS at Month 6.
Fast onset: 67.2% of participants graded by investigators as improved at Month 2, earliest measured time point.
No treatment-related SAEs or cardiac AESIs; common AEs were hypertrichosis and peripheral edema.
Topline results from Phase 2/3 Study '306' in female pattern hair loss expected in 1H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.